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Abstract 
Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors 
(TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and 
additional approaches to deplete CML LSC are needed to enhance the possibility of 
discontinuing TKI treatment. We have previously reported that expression of the pivotal pro-
inflammatory cytokine interleukin-1 (IL-1) is increased in CML bone marrow (BM). We show 
here that CML LSC demonstrated increased expression of the IL-1 receptors, IL-1RAP and IL-
1R1, and enhanced sensitivity to IL-1-induced NF-KB signaling compared to normal stem cells. 
Treatment with recombinant IL-1 receptor antagonist (IL-1RA) inhibited IL-1 signaling in CML 
LSC and inhibited growth of CML LSC. Importantly, the combination of IL-1RA with TKI resulted 
in significantly greater inhibition of CML LSC compared with TKI alone. Our studies also suggest 
that IL-1 signaling contributes to overexpression of inflammatory mediators in CML LSC, 
suggesting that blocking IL-1 signaling could modulate the inflammatory milieu. We conclude 
that IL-1 signaling contributes to maintenance of CML LSC following TKI treatment, and that IL-
1 blockade with IL-1RA enhances elimination of TKI-treated CML LSC. These results provide a 
strong rationale for further exploration of anti-IL-1 strategies to enhance LSC elimination in CML. 
 
Highlights 
• CML LSC demonstrate increased IL-1 receptor expression and enhanced signaling 
response 
• Inhibition of IL-1 signaling using the antagonist IL-1RA enhances targeting of CML LSC 
in combination with TKI 
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Introduction 
Chronic myelogenous leukemia (CML) results from hematopoietic stem cell (HSC) 
transformation by the BCR-ABL kinase.1 CML is characterized by a myeloproliferative disorder 
that progresses from initial chronic phase (CP) to accelerated phase (AP) and terminal blast 
crisis (BC). BCR-ABL tyrosine kinase inhibitors (TKI) are remarkably effective in inducing 
remissions, preventing transformation to BC, and prolonging survival of CML patients.2 However 
TKI treatment fails to eliminate CML leukemia stem cells (LSC), even in patients achieving deep 
molecular responses.3 Although a subset of CML CP patients are able to maintain remission 
after stopping TKIs, most patients require continued treatment to prevent relapse.4,5 The risks of 
prolonged treatment include toxicity, and considerable cost, which may affect adherence to 
treatment.6 Improved understanding of LSC resistance to TKI could help guide development of 
strategies to increase the proportion of CML patients achieving treatment-free remissions.  
We have studied LSC in CML using primary blood and bone marrow (BM) samples from CP 
CML patients, as well as an inducible transgenic mouse model of CML in which BCR-ABL is 
expressed under control of a Tet-regulated 3' enhancer of the murine stem cell leukemia (SCL) 
gene.7 Since in vivo characterization of human CML CP LSC in immunodeficient mice is limited 
by low levels of engraftment and lack of leukemia development, the transgenic mouse model 
has proven very useful to study CML LSC regulation and therapeutic strategies.8 We have found 
that leukemia-induced alterations in the BM microenvironment provide a competitive advantage 
to CML compared with normal long-term HSC (LTHSC). ELISA assays demonstrate increased 
expression of the pivotal pro-inflammatory cytokines IL-1α and IL-1β in the BM of BCR-ABL 
mice. IL-1α and IL-1β significantly increased growth of CML compared to normal LTHSC. BM 
cells from CML patients also demonstrated increased expression of IL-1α, but not IL-1β, 
compared to normal BM cells. IL-1α significantly increased expansion of CML compared to 
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normal CD34+CD38- cells. Interestingly IL-1α expression remained elevated in BM from CML 
patients in long-term remission on imatinib treatment.9  
IL-1 signals through the IL-1 receptor Type I (IL1-RI) and IL-1 receptor accessory protein (IL-
1RAP, IL-1R3) and activates the NF-KB, JNK, and p38 MAPK pathways. IL-1 signaling is 
enhanced in certain tumors, and associated with aggressive phenotype.10 Jaras et al. observed 
that IL-1RAP is selectively overexpressed in Philadelphia-positive (Ph+) CML stem cells, and 
that an anti-IL-1RAP antibody could target CML CD34+CD38- cells via antibody-dependent cell-
mediated cytotoxicity.11 However, the role of IL-1 signaling in TKI resistance of CML LSC is not 
known, and it is not known whether inhibiting IL-1 signaling could enhance elimination of CML 
LSC. IL-1 receptor antagonist (IL-1RA) is a member of the IL-1 cytokine family that binds non-
productively to IL-1R1, preventing IL-1α and IL-1β signaling. Recombinant human IL-1RA 
(Anakinra, Kinaret) is clinically approved for the treatment of rheumatoid arthritis.12 Here we 
evaluated the role of IL-1 signaling in CML LSC using IL-1RA, and studied it’s ability to 
modulate their sensitivity to TKI treatment.  
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Methods 
Mice: SCL-tTA/BCR-ABL mice in the CD45.1 FVB/N background (Huettner et al., 2005) were 
maintained on tetracycline. Recipient mice were in the CD45.2 FVBN background (kind gift from 
Dr Emmanuelle Passegue, UCSF). CD45.1 SCL-tTA/BCR-ABL mice crossbred with CD45.2 
mice to generate CD45.1.2 SCL-tTA/BCR-ABL mice were used as recipients for one experiment. 
Mouse care and experimental procedures followed federal guidelines and protocols were 
approved by the Institutional Animal Care and Use Committee at the City of Hope. 
Samples: Cord blood (CB) samples were provided by StemCyte (Arcadia, CA). Aliquots of 
normal peripheral blood (PB) and BM mononuclear cells (MNC) were obtained from transplant 
donors. CML BM samples were obtained from patients in CP who had not received TKI 
treatment from City of Hope and the University of Glasgow. Sample acquisition was approved 
by the Institutional Review Boards (IRB) at City of Hope and the North Glasgow University 
Hospital Division of NHS Greater Glasgow and Clyde in accordance with the Declaration of 
Helsinki.  All donors signed informed consent forms. MNC were isolated using Ficol separation. 
CD34+ cells were isolated using magnetic bead selection protocol (Miltenyi).  
Conditioned medium: To make conditioned medium (CM), 20 million fresh human or murine 
CML or normal MNCs were cultured in 10ml StemSpan™ Serum-Free Expansion Medium 
(SFEM) for 24 hours and the supernatant collected as CM. 
In vivo treatment of transgenic BCR-ABL mice: BM cells from BCR-ABL mice (CD45.1) were 
transplanted by tail vein into CD45.2 recipient mice (2x106 cells/mouse) irradiated at 900 cGy. 
Blood samples were obtained after 4 weeks to confirm development of neutrophilic leukocytosis. 
Mice were treated with NIL (Novartis, Basel, Switzerland) (50mg/kg/day, oral gavage), IL-1RA 
(Anakinra, Sobi, Stockholm, Sweden) (150mg/kg/day, s.c, ), NIL+IL-1RA, or vehicle for 3 weeks, 
euthanized, and PB, BM and spleen cells obtained. The IL-1RA dose was based on prior 
reports indicating that this dose inhibited IL-1 effects in mice.13 Donor derived CD45.1+ myeloid, 
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progenitor and stem cell populations were measured by flow cytometry. Long-term 
hematopoietic stem cells (LTHSC, LSK Flt3−CD150+CD48−), multipotent progenitors (MPP, LSK 
Flt3−CD150−CD48−, LSK Flt3−CD150+CD48+, LSK Flt3−CD150−CD48+), common myeloid 
progenitors, (CMP, Lin−Sca-1−c-Kit+CD34+Fc RII/IIIlo), and granulocyte-macrophage progenitors 
(GMP, Lin−Sca-1−c-Kit+CD34+Fc RII/IIIhi) were identified using flow cytometry. Pooled BM cells 
from treated mice were transplanted into CD45.2 mice (2×106cells/mouse). Engraftment in PB 
was monitored every 4 weeks. The fraction of mice developing leukemia, manifested by 
neutrophilic leukocytosis, within 16 weeks was determined and survival was monitored. Another 
cohort of mice was treated with NIL or NIL+IL-1RA for 4 weeks, and monitored for survival after 
treatment discontinuation. 
In vitro proliferation, apoptosis, colony forming assays: Human CD34+ cells were labeled 
with 1.25μM CFSE (Molecular Probes, Eugene, OR) and antibodies, and flow cytometry sorted 
to collect CD34+CD38− and CD34+CD38+ cells with uniform CFSE labeling.14 Cells were 
cultured with human normal or CML BM CM with IL-1RA (5µg/mL), NIL (5µM) or the 
combination for 72 hours. Cell numbers were measured by Lumino Glo (Promega). To measure 
apoptosis and proliferation, cells were labeled with Annexin V (BD, San Diego, CA) and 
analyzed by flow cytometry for Annexin V and CFSE fluorescence.14 ModFit software (Verity, 
Topsham, ME) was used to assess the different cell generations and proliferation index. For 
colony-forming cell (CFC) assays, cells were plated in methylcellulose progenitor culture burst-
forming units-erythroid and colony-forming units-granulocyte and macrophage counted after 14 
days. Colony replating assays were performed by collecting and pooling colonies from primary 
CFC assays and plating 10,000 cells in secondary CFC assays. 
Engraftment of human cells in immunodeficient mice: CML CD34+ cells (1×106 cells/mouse) 
or CB CD34+ cells (1×105 cells/mouse) were cultured in CML CM for 72 hours with NIL (5μM), 
IL-1RA (5µg/mL), or the combination, and transplanted via tail vein into sublethally irradiated 
(300 cGy) 8 weeks old NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ mice (NSG mice, The Jackson 
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Laboratory, Bar Harbor, ME). Mice were euthanized after 4 or 16 weeks, and BM and blood 
cells obtained at necropsy. Human CD45 expressing cells were enumerated by flow cytometry. 
Q-PCR analysis was performed using primer and probe sequences for BCR-ABL (B3A2 or 
B2A2) (Branford et al., 1999). Human BCR levels were measured as internal controls. 
IL-1 receptor and signaling assays: IL-1 receptor Type I (IL1-RI, R&D Systems, cat: FAB269A) 
and IL-1 receptor accessory protein (IL-1RAP, R&D systems, cat: FAB676P) expression was 
measured by flow cytometry. To assess IL-1 signaling, CD34+ cells from CB, normal BM and 
CML BM were cultured in SFEM with IL-1α (10 ng/mL, Peprotech, cat: 200-01A), or in CML or 
normal BM CM, for 16 hours and p-NF-KB (p65) (BD, cat: 558422), p-p38 MAPK (BD, cat: 
612594) and p-JNK (BD, cat: 562480) expression measured by flow cytometry. To measure 
effects of IL-1RA and NIL, CML Lin-CD34+CD38-CD90+ cells were cultured in CML BM CM 
with IL-1RA (5µg/ml), NIL (5µM) or the combination for 24 hours. Cells were analyzed by flow 
cytometry for p-CrkL (Cell signaling, cat: 3181), p-NF-KB, p-p38 MAPK and p-JNK expression. 
Results were expressed as ratio of median channel fluorescence (MCF) to isotype controls.  
RT-Q-PCR analysis: Human CML BM CD34+CD38-CD90+ cells were cultured in CML CM with 
IL-1RA (5µg/ml), NIL (5µM) or the combination for 24 hours. RNA was extracted and first strand 
cDNA synthesized from 200 cells, pre-amplified for 18 cycles, and multiplex RT-Q-PCR 
performed using TaqMan Assays (Thermo Fisher Scientific, Waltham, MA, Table 1) and the 
Fluidigm Biomark system. Results were expressed as ratio to β2m.  
Analysis of microarray data: Data were obtained from GEO (GSE12211) and normalized 
using affy::rma in R.15  Differential expression was calculated using LIMMA, using a paired-
sample design.  Gene annotations were obtained from hgu133a2.db library in R. Gene set 
enrichment analysis (GSEA) was performed using GSEA software (Broad Institute). 
Immunofluorescence analysis: CML CD34+CD38-CD90+ cells cultured in CML CM with NIL 
(5µM), IL-1RA (5µg/mL), or the combination for 24 hours were spun onto glass slides. Cells 
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were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and incubated 
with RelA/NF kappa B p65 antibody (MAB5078, R&D Systems), and FITC–conjugated anti-
mouse secondary antibodies. Slides were examined using a Zeiss upright LSM 510 2-photon 
confocal microscope. 
Enzyme-linked immunosorbant assays (ELISA): ELISA was performed, using R&D Systems 
human IL-1α Quantikine ELISA kit (DLA50), according to the manufacturer’s protocol.  
 
Statistics: Data were reported as the mean ± SEM. Student’s t-test, and one or two-way 
ANOVA with multiple testing were performed to determine statistical significance, as 
appropriate. P < 0.05 was considered statistically significant. 
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Results 
IL-1RA inhibits growth of murine CML stem cells  
We have previously shown that CML LTHSC have a significant growth advantage over normal 
LTHSC when cultured in CML compared to normal BM CM.9 To evaluate the role of IL-1 within 
CML BM CM in regulating CML LTHSC growth, LTHSC from SCL-tTA/BCR-ABL mice (CD45.1) 
were mixed in a 1:1 ratio with LTHSC from congenic FVBN mice (CD45.2), and cultured for 7 
days with CML BM CM with and without IL-1RA to block IL-1 receptor signaling. The ratio of 
CML to normal LTHSC was significantly decreased by IL-1RA (Figure 1A), indicating that IL-
1RA reduced the growth advantage of CML LTHSC. 
To analyze effects of IL-1RA on in vivo growth of CML LSC, BM cells from SCL-tTA/BCR-ABL 
and congenic FVBN mice were mixed in a 1:1 ratio and transplanted into irradiated BCR-ABL 
recipient mice (CD45.1.2). BCR-ABL expression was induced in recipient mice for 4 weeks prior 
to transplant, to generate leukemia-related changes in the BM microenvironment. Mice were 
treated with IL-1RA or vehicle. The ratio of CML to normal cells was significantly reduced in PB 
of IL-1RA-treated compared with control mice after 4 weeks (Figure 1B). Subsequent withdrawal 
of IL-1RA resulted in return of CML to normal cell ratios to levels similar to controls. 
IL-1RA enhances elimination of murine CML stem cells treated with nilotinib (NIL) 
To test the effect of IL-1RA by itself and in combination with NIL on CML LTHSC in vivo, BM 
cells from SCL-tTA/BCR-ABL mice (CD45.1) were transplanted into congenic FVBN mice 
(CD45.2) to generate a cohort of mice with CML-like disease. This approach allows generation 
of a large number of mice with similar time of onset of leukemia, facilitating studies of 
therapeutic interventions against CML stem cells.8 Following CML development 4 weeks after 
transplantation, mice were treated with IL-1RA, NIL, or the combination for 3 weeks. WBC 
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counts were reduced after treatment with IL-1RA, NIL and the combination (Figure 1C). IL-1RA 
and the IL-1RA plus NIL combination reduced spleen cellularity (Figure 1D). The combination of 
NIL and IL-1RA significantly reduced the percentage of engraftment of CD45.1+ CML cells in 
PB (Figure 1E), BM (Figure 1F) and spleen (Figure 1G), and further reduced CML engraftment 
in BM, but not in blood and spleen, compared to NIL alone. IL-1RA or NIL alone did not reduce 
CML BM LTHSC (Figure 1H) and MPP (Figure 1I), whereas the combination of IL-1RA and NIL 
significantly reduced CML LTHSC and MPP compared to controls and NIL alone. Finally, IL-
1RA, NIL and the combination did not reduce CML CMP (Figure 1J) and GMP (Figure 1K) in the 
BM. IL-1RA did not significantly affect the number of CML LTHSC (Figure S1A), CMP (Figure 
S1C) and GMP (Figure S1D) in the spleen, although MPPs (Figure S1B) were reduced. NIL and 
the combination of NIL plus IL-1RA did not affect LTHSC, but significantly reduced MPP, CMP 
and GMP in the spleen of CML mice (Figure S1A-D). Thus combination treatment results in 
enhanced inhibition of BM cells, particularly stem and progenitor populations, but does not 
significantly inhibit mature cells in blood and spleen or splenic LTHSC. 
Secondary transplantation of BM cells from CML mice (CD45.1) treated with NIL plus IL-1RA 
into wild -type recipient mice (CD45.2) was associated with significantly reduced WBC counts 
(Figure 2A), reduced percentage of CML cell engraftment (Figure 2B), reduced leukemia 
development (Figure 2C), and significantly prolonged survival, compared to untreated controls 
(Figure 2D). Mice treated with NIL or the combination of NIL and IL-1RA for 4 weeks were also 
followed for survival. Mice treated with both IL-1RA and NIL showed markedly improved survival 
after stopping treatment (Figure 2E). These results indicate that addition of IL-1RA to NIL 
enhances inhibition of BM LSC capable of engrafting secondary recipients and causing disease 
relapse. 
IL-1RA inhibits growth of human CML stem cells treated with NIL 
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To study the effect of IL-1RA on human CML stem and progenitor cells, CML and normal 
CD34+CD38- stem/progenitor cells and CD34+CD38+ committed progenitors were cultured in 
CML BM CM and exposed to NIL (5µM), IL-1RA (5µg/mL) or NIL+IL-1RA for 72 hours. A dose-
response analysis showed that the IL-1RA concentration used achieved maximal in vitro 
inhibitory effects (Figure S2A). IL-1RA significantly inhibited CML CD34+CD38- cell growth 
(Figure 3A), cell division (Figure 3B, E) and CFC frequency (Figure 3C), and increased 
apoptosis (Figure 3D, E), compared with NIL or IL-1RA alone. The combination of NIL and IL-
1RA also significantly reduced CML CD34+CD38+ cell growth (Figure S2B), cell division (Figure 
S2C) and CFC frequency (Figure S2D), but did not change apoptosis, compared with NIL alone 
(Figure S2E). The combination of IL-1RA and NIL significantly inhibited replating capacity of 
CML CFC compared to controls and NIL alone (Figure 3F). In contrast, no significant inhibition 
of cell growth, cell division and CFC frequency, or increase in apoptosis, was seen in normal 
CD34+CD38- (Figure 3A-D) or CD34+CD38+ cells (Figure S2B-E) treated with NIL, IL-1RA, or 
the combination. 
To test effects on in vivo engraftment, CML and normal CD34+ cells were treated with IL-1RA, 
NIL, or IL-1RA plus NIL for 72 hours and transplanted into NSG mice. IL-1RA plus NIL treatment 
reduced short-term (4 weeks, Figure 3G) and long-term (16 weeks, Figure 3H) engraftment in 
BM, compared with no treatment, or IL-1RA or NIL alone. IL-1RA, NIL and IL-1RA plus NIL all 
resulted in significant reduction of BCR-ABL+ cells in BM at 16 weeks, assessed by RT-Q-PCR 
analysis, compared with untreated controls (Figure 3I). The observed reduction in human cell 
engraftment taken together with the similar BCR-ABL levels indicates that leukemic cell 
engraftment is reduced with combination treatment compared to NIL alone. IL-1RA, NIL or the 
combination did not significantly affect engraftment of CB CD34+ cells in PB of NSG mice at 4 
weeks (Figure S2F), and in PB (Figure S2G), or BM (Figure S2H) at 16 weeks, compared with 
untreated controls. Taken together these results indicate that IL-1RA when combined with NIL 
selectively and effectively targets primitive CML cells that resist elimination with NIL alone. 
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Increased IL-1 receptor expression in CML LSC 
We studied expression of the IL-1 receptor components, IL-1 receptor-associated protein (IL-
1RAP) and IL-1R1, on human CML and normal CD34+CD38-CD90+ stem cells and CD34+ 
progenitor cells (Figure S3A). Consistent with previous reports, IL-1RAP was expressed on 
CML but not normal stem cell populations (Figure 4A).11 We also observed a significant 
increase of IL-1R1 expression on CML stem cells (Figure 4B). Expression of IL-1RAP and IL-
1R1 was also increased on CML compared with normal CD34+ cells (Figure S3B, C). We 
evaluated IL-1α and IL-1β levels in PB from CML CP patients and healthy controls by ELISA. IL-
1α but not IL-1β expression was enhanced in several CML patients, and average IL-1α levels 
were increased compared to normal PB (Figure 4C). Exposure to IL-1α did not affect the 
expression of IL-1R1 and IL-1RAP on human CML stem cells (Figure 4D), and reduced IL-
1RAP expression in murine CML stem cells (Figure S3D). Exposure to human CML or normal 
BM CM did not affect the expression of IL-1R1 and IL-1RAP on CML (Figure 4E) or normal 
(Figure 4F) stem cells. 
We studied the effect of TKI treatment on IL-1R1 and IL1-RAP expression using data from 
Bruennert et al analyzing changes in the transcriptome of CD34+ cells from CML patients after 
7 days of imatinib treatment.16 We observed that IL-1 receptor expression in CML progenitors 
was not changed after TKI treatment (Figure 4G). 
 
IL-1RA and NIL inhibit inflammatory signaling in CML LSC 
IL-1α signals through the NF-KB, p38-MAPK and p-JNK pathways.17 Exposure to IL-1α 
increased expression of p-NF-KB (p65) (Figure 5A), p-p38 MAPK (Figure 5B) and p-JNK (Figure 
5C) in CML, but not normal stem cells, as evaluated by flow cytometry. IL-1α also increased 
expression of p-NF-KB (p65) (Figure S4A) and p-p38 MAPK (Figure S4B), but not p-JNK (Figure 
S4C), in CML but not normal CD34+ cells. Exposure to IL-1α also increased expression of p-
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p38 MAPK and p-JNK in murine CML stem cells (Figure S4D). These results indicate that CML 
stem cells demonstrate an enhanced signaling response to IL-1 stimulation. CML stem cells 
demonstrated enhanced NF-kB activity (Figure 5D), no change in p-p38 activity (Figure 5E), and 
enhanced p-JNK activity (Figure 5F) after exposure to CML compared to normal BM CM. On the 
other hand CML or normal CM did not increase NF-kB, p-p38 or p-JNK signaling in normal stem 
cells (Figure 5G-I).  
We evaluated the effect of IL-1RA, NIL or the combination on p-NF-KB (p65), p-p38 MAPK and 
p-JNK expression in CML LSC cultured in CML BM CM. Significant reduction of p-NF-KB levels 
was seen with IL-1RA or NIL alone, with further reduction with the combination (Figure 6A). 
Treatment with IL-1RA or NIL alone significantly inhibited p-p38 MAPK levels (Figure 6B), but 
did not inhibit p-JNK levels (Figure 6C). The combination of IL-1RA and NIL significantly 
reduced both p-p38 MAPK and p-JNK expression. Our results indicate that combination 
treatment results in additional inhibition of NF-kB signaling, but not P38 MAPK or JNK signaling 
compared to NIL alone (Figures 6B, 6C, and S4F). Similar effects were seen in CML CD34+ 
cells (Figure S4E-G). Expression of p-CrkL was reduced in CML stem cells (Figure 6D) and 
CD34+ cells (Figure S4H) treated with NIL, indicating effective BCR-ABL kinase inhibition. 
Immunofluorescence analysis showed reduced expression of both nuclear and cytoplasmic NF-
KB p65 in CML stem cells treated with IL-1RA compared with controls (Figure 6E). NIL 
treatment also resulted in reduction in NF-κB levels, with maximal reduction seen with the 
combination of IL-1RA and NIL. GSEA analysis also indicated significant inhibition of NF-kB 
related genes in CD34+ cells from CML patients treated with imatinib for 7 days, compared to 
untreated patients (Figure S4I). RT-Q-PCR analysis showed that NIL treatment reduced 
expression of the NF-κB target genes BCL2L1 but not NFKB1A and BIRC3. On the other hand, 
treatment with IL-1RA and the combination of NIL and IL-1RA resulted in significant reduction in 
NFKB1A (Figure 7A), BCL2L1 (Figure 7B), and BIRC3 (Figure 7C), indicating additional effects 
of IL-1 inhibition on NF-kB signaling in CML stem cells beyond those seen with TKI treatment.  
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Since NF-kB signaling can enhance expression of several inflammatory cytokines, we evaluated 
the effects of IL-1RA and NIL on cytokine gene expression in CML LSC.17 Q-RT-PCR analysis 
revealed reduced expression of IL-1α, but not IL-1β, with IL-1RA treatment (Figure 7D, E), and 
reduced expression of IL-6 (Figure 7F), CXCL1 (Figure 7G), CCL2 (Figure 7I), CCL3 (Figure 7J), 
CCL4 (Figure 7K) and TNF-α (Figure 7L) with IL-1RA and IL-1RA plus NIL, compared to 
controls. NIL treatment reduced expression of IL-6 (Figure 7F), CXCL2 (Figure 7H), and TNF-α 
(Figure 7L), but not other cytokines. These observations suggest that blocking IL-1 signaling 
modulates expression of inflammatory mediators in CML cells. 
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Discussion 
IL-1 receptors are expressed in HSC during fetal development and regulate their 
differentiation.18,19 IL1R-deleted adult mice do not show defects in steady-state hematopoiesis.20 
The studies of Ågerstam et al. (manuscript cosubmitted to Blood) confirm that IL-1RAP is 
dispensable for normal HSC function, even under conditions of hematopoietic stress. However, 
chronic IL-1 exposure can drive myeloid differentiation, and chronic exposure leads to reduced 
HSC self-renewal21. Consistent with previous reports, we observed that CML LTHSC 
demonstrated upregulated IL-1RAP expression.11 Our studies and those of Agerstam et al. 
show that CML LSC also demonstrated increased expression of the co-receptor IL-1R1. 
Increased expression of the IL-1 receptor complex may explain enhanced IL-1 responsiveness 
in CML LSC. IL-1RAP is also expressed in stem cells from patients with acute myeloid leukemia 
(AML), raising the possibility of similar activity in this leukemia.22,23  
IL-1 is a primary regulator of inflammatory and innate immune responses. IL-1 receptor 
engagement initiates a complex sequence of phosphorylation and ubiquitination events resulting 
in activation of the NF-KB, JNK and p38 MAPK pathways, and rapid increase in expression of a 
large number of immediate early genes central to the inflammatory response.17 Canonical 
IL-1 target genes include cytokines such as IL-6, IL-8, TNF-α, MCP-1, IL-1α, IL-1β, and MKP-1. 
The intracellular components that participate in IL-1 signaling also mediate responses to other 
cytokines. For example, autocrine TNF-α production by CML stem/progenitor cells also supports 
their survival by promoting NF-κB/p65 activation.24 Although other cytokines overexpressed in 
the CML BM microenvironment could have redundant effects, the observation that IL-1RA 
effectively inhibits downstream signaling through NF-KB, supports a central regulatory role of IL-
1. Indeed IL-1 inhibition diminishes expression of several other cytokines in CML LSC. 
IL-1 signaling is regulated at the level of synthesis and release, membrane receptors, and 
intracellular signal transduction. Both increased IL-1 levels in the CML BM microenvironment, 
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and increased receptor expression may play a role in enhanced signaling in CML LSC. BCR-
ABL kinase mediated modulation of intracellular signaling mechanisms could also contribute to 
increased IL-1 responsiveness. NF-κB is activated through the canonical IKK pathway in BCR-
ABL+ cells, and contributes to the pathogenesis of myeloid and lymphoid leukemia.25,26 IL-1 
stimulation induces miR-146a expression, which acts as a negative feed-back regulator of IL-1 
signaling by inhibiting the IRAK1 and TRAF6 genes.27,28 Our recent studies show that miR-146a 
is downregulated in CML CD34+ cells, potentially contributing to increased IL-1 signaling.29 
Further evaluation of this mechanism is warranted in future studies. The studies of Agerstam et 
al., and our own analyses, show that IL-1 receptor expression on CML LSC is not reduced by 
BCR-ABL kinase inhibition. Agerstam et al. further show that TKI-treated CML stem cells 
maintain signaling responses to IL-1 stimulation. This is consistent with our results showing that 
treatment with TKI inhibits NF-kB signaling in CML LSC, but that even greater inhibition is seen 
after addition of IL-1RA.  
Our data suggests that microenvironmental IL-1 mediated signaling contributes to resistance of 
CML LSC to TKI. IL-1RA had modest effects on CML stem cell maintenance by itself in the 
context of active BCR-ABL signaling, but when combined with NIL resulted in significantly 
enhanced inhibition of CML stem cells compared with NIL alone. Currently, only a small fraction 
of TKI-treated CML patients can maintain treatment-free remissions (TFR) after discontinuing 
treatment.30 Our studies support further exploration of the use of IL-1 blockade as a potential 
strategy to enhance LSC targeting in patients receiving TKI treatment to increase the likelihood 
of achieving TFR. Anakinra has been extensively used to treat rheumatoid arthritis, and has 
been well tolerated with an excellent safety profile, making it an attractive candidate for further 
evaluation.31 Other strategies to limit IL-1 activity approved for treating chronic inflammatory 
diseases include neutralizing antibodies to IL-1β and a soluble receptor for IL-1.12 Importantly, 
the companion paper by Agerstam al. also shows that antibodies against IL-1RAP reduce 
leukemia in an in vivo model of CP CML. In conclusion, our studies reveal a role for IL-1 
17 
mediated inflammatory signaling in maintenance of CML LSC in TKI-treated CML patients, and 
support targeting of this mechanism as a strategy to enhance LSC elimination in combination 
with TKI. 
18 
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Table 1. Gene expression assays used for RT-Q-PCR 
 
 
NFκB1α Hs00355671_g1 
BCL2L1 Hs00236329_m1 
BIRC3 Hs00985031_g1 
IL-1α Hs00174092_m1 
IL-1β Hs00174097_m1 
IL-6 Hs00985639_m1 
CXCL1(KC) Hs00236937_m1 
CXCL2(MIP2) Hs00601975_m1 
CCL2 (MCP-1) Hs00234140_m1 
CCL3 (MIP-1-alpha) Hs00234142_m1 
CCL4 (MIP-1-beta) Hs99999148_m1 
TNF-α Hs01113624_g1 
IL-17 Hs00174383_m1 
CD83 Hs00188486_m1 
β2M Hs00187842_m1 
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Figures and figure legends 
 
Figure 1. IL-1RA inhibits growth of murine CML stem cells and enhances elimination of 
CML stem cells in combination with Nilotinib. CML (CD45.1) and normal (CD45.2) LTHSC 
were mixed with in a 1:1 ratio and cultured in murine CML BM CM with or without IL-1RA 
(2.5µg/ml) for 7 days. The ratio of CD45.1+ to CD45.2+ cells is shown (A).  BM cells from CML 
(CD45.1) and control (CD45.2) mice were mixed in a 1:1 ratio and transplanted into irradiated 
CML recipient mice (CD45.1.2). The recipient mice were treated with or without IL-1RA 
(150mg/kg/d, s.c.) for 4 weeks. The ratio of CML to control cells is shown in (B). BM cells from 
BCR-ABL mice (CD45.1) were transplanted by tail vein injection (2x106 cells/mouse) into 
recipient mice (CD45.2). Mice were treated with IL-1RA (150mg/kg/day, s.c.), NIL (50mg/kg/day, 
oral gavage), IL-1RA+NIL, or vehicle for 3 weeks (n=10 each). PB WBC count (C); spleen 
weight (D); percentage CD45.1+ cells in PB (E), BM (F) and spleen (G); and number of LTHSC 
(H), MPP (I), CMP (J) and GMP (K) in the BM are shown. Results represent mean±SEM. 
Significance values: * p<0.05; ** p<0.01; *** p<0.001, 2-way ANOVA. 
 
Figure 2. IL-1RA enhances elimination of CML stem cells in combination with Nilotinib. 
BM cells from CML mice (CD45.1) treated with IL-1RA alone, NIL alone or IL-1RA in 
combination with NIL were transplanted into irradiated secondary recipient mice (CD45.2) (n=8 
each). White blood cell counts (A), percent CD45.1 engraftment in PB (B), frequency of the 
mice developing leukemia (C), and survival (D) of the secondary recipient mice is shown. 
Another cohort of mice (n=7 each) was treated with NIL alone or combination of NIL and IL-1RA 
for 4 weeks following which treatment was stopped and the survival of these mice was shown 
23 
(D). Results represent mean±SEM. Significance values: *, p<0.05; **, p<0.01, 2-way ANOVA 
and log-rank test. 
 
Figure 3. IL-1RA inhibits growth of human CML stem cells in combination with Nilotinib. 
Primary human CML and normal CD34+CD38- primitive stem/progenitor cells were cultured in 
human CML BM CM and exposed to NIL (5μM), IL-1RA (5μg/mL), NIL+IL-1RA, or vehicle for 72 
hours. Cell growth (A), cell proliferation (B), CFC (C) and apoptosis (D) was shown. A 
representative flow cytometry plot showing CFSE and Annexin V labeling is shown (E). CD34+ 
cells treated with NIL, IL-1RA, and NIL+IL-1RA were plated in CFC assays (left) and after 14 
days colonies were harvested and cells resuspended and re-plated in secondary CFC assays 
(right)(F). CML CD34+ cells treated with IL-1RA, NIL, or IL-1RA in combination with NIL for 72 
hours were transplanted into irradiated (300cGy) NSG mice (n=6 each). Engraftment of human 
CD45+ cells in the BM of NSG mice at 4 weeks (G) and 16 weeks (H) is shown. BCR/ABL 
expression in the enriched human CD45+ cells in the BM at 16 weeks was measured (I). 
Results represent mean±SEM. Significance values: *, p<0.05; **, p<0.01; ***, p<0.001, 2-way 
ANOVA, 1-way ANOVA. 
 
Figure 4. Increased IL-1 receptor expression in CML LSC.  IL-1RAP (A) and IL-1R1 (B) 
expression on human CML and normal CD34+CD38-CD90+ stem cells measured by flow 
cytometry. IL-1α levels in peripheral blood of CML patients and healthy controls measured by 
ELISA (C). Effect of human IL-1α exposure on IL-1R1 and IL-1RAP expression in CML stem 
cells (n=4) (D). Effect of human CML and normal BM CM on IL-1R1 and IL-1RAP expression in 
CML (n=4) (E) and normal (n=3) (F) stem cells. IL-1R1 and IL1-RAP mRNA expression in 
CD34+ cells from CML patients after 7 days of imatinib treatment, as measured in microarray 
analysis, with two separate probes for each gene (G). Results represent mean±SEM. 
Significance values: *, p<0.05; **, p<0.01, unpaired t-test, 2-way ANOVA. 
24 
 
Figure 5. Increased IL-1 signaling in CML LSC.  CML and normal CD34+CD38-CD90+ stem 
cells were exposed to IL-1α (10ng/mL) for 16 hours and expression of p-NF-KB (p65) (A), p-p38 
MAPK (B) and p-JNK (C) was measured by flow cytometry. Expression of p-NF-KB (p65) (D), p-
p38 MAPK (E) and p-JNK (F) in CML HSC (n=4) exposed to human CML and normal CM for 16 
hours. p- NF-KB (p65) (G), p-p38 MAPK (H) and p-JNK (I) expression in normal HSC (n=3) 
exposed to CML and normal CM. Results represent mean±SEM. Significance values: *, p<0.05; 
**, p<0.01; ***, p<0.001, 2-way ANOVA, unpaired t-test. 
 
Figure 6. IL-1RA in combination with Nilotinib inhibits inflammatory signaling in CML 
LSC. CML LTHSC (Lin-CD34+CD38-CD90+ cells) were cultured in CML BM CM in the 
presence of IL-1RA, NIL or combination of IL-RA and NIL for 24 hours. The expression of p- NF-
KB p65 (A), p38 MAPK (B), p-JNK (C) and p-Crkl (D) by flow cytometry is shown. Nuclear 
localization of NF-κB p65 protein in stem cells treated with IL-1RA, NIL or the combination of IL-
1RA and NIL was evaluated by immunofluorescence analysis (E). Results represent 
mean±SEM. Significance values: *, p<0.05; **, p<0.01; ***, p<0.001, 1-way ANOVA. 
 
Figure 7. IL-1RA in combination with Nilotinib inhibits NF-kB target gene and cytokine 
gene expression in CML LSC. Expression of the NF-κB target genes, NFKB1A (A), BCL2L1 
(B) and BIRC3 (C) and the inflammatory cytokines, IL-1α (D), IL-1β (E), IL-6 (F), CXCL1 (G), 
CXCL2 (H), CCL2 (I), CCL3 (J), CCL4 (K) and TNF-α (L) in CML CD34+CD38-CD90+ cells 
treated with IL-1RA, NIL, or the combination of NIL and IL-1RA was measured by Q-RT-PCR.  
Results represent mean±SEM. Significance values: *, p<0.05; **, p<0.01, paired t-test.  
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